GILD Gilead Sciences Inc.

Gilead Sciences Announces Second Quarter 2017 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)--

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.52 per share of common stock for the second quarter of 2017. The dividend is payable on June 29, 2017, to stockholders of record at the close of business on June 16, 2017. Future dividends will be subject to Board approval.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

EN
02/05/2017

Underlying

GILDGilead Sciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Gilead Sciences Inc.

Free Trial
GILD Gilead Sciences...

Gilead Sciences Inc: 1 director

A director at Gilead Sciences Inc sold/sold after exercising options 10,000 shares at 111.656USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...

GILD GILEAD SCIENCES INC.
10/01/25 October 1, 2025 1 EN
GILD Gilead Sciences...

Moody's Ratings affirms Gilead's A3 rating; revises outlook to positiv...

Moody's Ratings (Moody's) affirmed the ratings of Gilead Sciences, Inc. ("Gilead") including the A3 senior unsecured ratings and (P)A3 senior unsecured shelf rating. At the same time, we revised the outlook to positive from stable. The positive outlook reflects positive momentum in Gilead's pipeli...

GILD GILEAD SCIENCES INC.
09/18/25 September 18, 2025 1 EN
GILD GILEAD SCIENCES INC.
12/18/24 December 18, 2024 1 EN
EUR 153.31
GILD Gilead Sciences...

Moody's Ratings assigns A3 rating to Gilead's notes; stable outlook

Moody's Ratings (Moody´s) assigned an A3 rating to the new senior unsecured notes issuance of Gilead Sciences, Inc. ("Gilead"). There are no changes to Gilead's existing ratings including the A3 senior unsecured ratings, (P)A3 senior unsecured shelf or the stable outlook. Proceeds of the offering ...

GILD GILEAD SCIENCES INC.
11/13/24 November 13, 2024 1 EN
EUR 212.93
GILD Gilead Sciences...

Gilead Sciences, Inc.: Update to credit analysis

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

GILD GILEAD SCIENCES INC.
10/28/24 October 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch